J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347

Short Report

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)

Marco Bregni, Fabio Ciceri, Jacopo Peccatori

Department of Hematology, Istituto Scientifico San Raffaele, Milano, Italy

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Citation:
Bregni M, Ciceri F, Peccatori J. Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347. Available from http://www.jcancer.org/v02p0347.htm

File import instruction

Abstract

A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.

Keywords: Allogeneic hematopoietic stem cell transplantation, advanced renal cell cancer, graft-versus-tumor.